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Abstract
Functional mitral regurgitation, a common problem in patients with left ventricular sys-
tolic dysfunction, has a strong negative impact on prognosis. Beneficial effects of surgical 
treatment in functional mitral regurgitation are still a matter of debate. Thus, cardiac 
dyssynchrony, a factor involved in functional mitral regurgitation pathophysiology, may 
become a therapeutic target in patients with this condition. This part of the book pres-
ents the pathophysiology of functional mitral regurgitation as a dynamic process, with 
particular emphasis on cardiac dyssynchrony, as both a contributor to functional mitral 
regurgitation and a target for cardiac resynchronization therapy. The underlying mecha-
nisms of success and failure in the resynchronization therapy are discussed, along with 
therapeutic approaches to symptomatic patients with severe left ventricular dysfunction 
and significant persistent functional mitral regurgitation.
Keywords: functional mitral regurgitation, left ventricular remodeling, cardiac 
dyssynchrony, cardiac resynchronization therapy
1. Introduction
Secondary (functional) mitral regurgitation (MR) is a common finding in patients with global 
left ventricular (LV) dilatation and dysfunction, in both ischemic and non-ischemic cardiomy-
opathy. This functional disorder of the mitral valve is more common and far more complex 
than organic MR. In secondary MR, mitral valve is structurally normal (or almost normal) but 
its geometry and function are disrupted due to an imbalance between closing and tethering 
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forces secondary to alterations in the geometry and function of the left ventricle. Functional 
MR can promote progressive LV remodeling. This results in a vicious circle, with both LV dil-
atation and functional MR acting as self-perpetuating processes. While prognosis is affected 
only in severe organic MR, even a mild functional MR may significantly worsen the out-
come. However, it is unclear whether the unfavorable impact of functional MR on prognosis 
is independent of underlying LV dysfunction. We still do not know if mitral valve surgery, 
effective in the treatment of organic diseases of the mitral valve, can be equally beneficial in 
functional MR, since the surgical correction of valve dysfunction does not reverse the under-
lying LV pathology. Thus, indications for mitral valve surgery in heart failure (HF) patients 
with functional MR are not well defined in any currently available guidelines. Also the role of 
other treatment modalities, such as medical and interventional therapies, still raises contro-
versies because of their limited effectiveness in functional MR management. This is related to 
both the underlying heart disease and the complexity of functional MR phenomenon. Also, 
adequate assessment of functional MR mechanisms and severity by means of imaging studies 
prior to making any therapeutic decisions constitute a challenge for clinicians. Cardiac dys-
synchrony is a mechanism that provides a pathophysiologic basis for potential improvement 
of functional MR after the use of cardiac resynchronization therapy (CRT).
This part of the book presents the pathomechanism of functional MR with particular empha-
sis on the influence of cardiac dyssynchrony on mitral valve function, as well as the mecha-
nisms of MR improvement after implantation of a CRT device, and prognostic value of both 
functional MR and its regression in response to CRT in patients with chronic heart failure.
2. Incidence and importance of functional mitral regurgitation in left 
ventricular dysfunction
Functional MR is a common, but often ‘silent,’ finding in heart failure patients [1–6]. Reported 
prevalence of functional MR varies depending on a diagnostic method (angiography, color 
Doppler echocardiography) and heart failure etiology (ischemic, non-ischemic) [1–5]. The 
incidence of functional MR after myocardial infarction varies from 20 to 50% but exceeds 50% 
in patients with non-ischemic dilated cardiomyopathy [4–6]. According to general estimates, 
nearly a half of heart failure patients may have a functional MR of some degree, and approxi-
mately one-third of them may suffer from moderate or severe functional MR [1, 3, 7].
Functional MR is an independent predictor of worse prognosis in patients with either ischemic 
or non-ischemic etiology of heart failure [3]. In patients with non-ischemic LV dysfunction, 
functional MR is associated with a two- to three-fold increased risk of heart failure episodes 
and cardiac mortality [4]. After myocardial infarction the presence of at least moderate func-
tional MR is associated with a 3-fold increased risk of heart failure and a 1.6-fold increased 
risk of death at the 5-year follow-up [2]. Assessment of mitral valve function is included in 
routine risk stratification after myocardial infarction.
Functional MR is present in a large proportion of patients eligible for cardiac resynchronization 
therapy, with the incidence varying slightly from population to population and depending 
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on the evaluation method. Significant—that is, at least moderate—functional MR is present in 
about 40% of patients qualified to CRT [8–10]. Nowadays, functional MR no longer disquali-
fies patients from resynchronization therapy if such treatment is indicated. Furthermore, a 
decrease in functional MR severity is a determinant of response to CRT [10–12].
3. Difficulties in echocardiographic quantification of functional 
mitral regurgitation
Adequate evaluation of functional MR requires detailed clinical information (including 
functional NYHA class), physical examination, electrocardiography, and imaging studies. 
Echocardiography is essential for the evaluation of mitral valve anatomy and quantification 
of MR severity [13]. Transthoracic and transesophageal echocardiography may provide com-
plementary clinically useful information, especially in the context of surgical or transcath-
eter repair feasibility. Usually, transesophageal echocardiography is more suitable for the 
evaluation of underlying anatomical conditions and identification of functional MR mecha-
nism. However, due to changes in LV loading conditions during transesophageal evaluation 
(vasodilatory effect of sedation, hypovolemia, or anesthesia), the severity of functional MR 
may be underestimated; this favors transthoracic echocardiography as a method to quantify 
mitral regurgitation. Moreover, transthoracic examination is more suitable for the evaluation 
of other important parameters, such as LV volume, function and sphericity, left atrial size, 
pulmonary artery pressure, and function of the right ventricle and tricuspid valve. Three-
dimensional (3D) echocardiography (either transesophageal or transthoracic) may provide 
additional information about MR severity, especially with regard to noncircular orifice geom-
etry in functional MR [14]. 3D echocardiography overcomes some limitations of two-dimen-
sional (2D) imaging; for example, it can be used for direct planimetric measurement of vena 
contracta area, a parameter which corresponds directly to the effective regurgitant orifice area 
(EROA) irrespective of the orifice shape or number of jets. However, both 3D and 2D color 
Doppler flows tend to overestimate the jet area (volume) due to their known bias in correct 
assessment of a turbulent stream. Considering all the difficulties previously mentioned, it 
needs to be stressed that no single parameter (also “quantitative”) is sufficient to adequately 
assess the severity of functional MR and thus, this condition should be evaluated with mul-
tiple methods [14].
In practical terms, echocardiographic severity of MR can be graded as mild, moderate or 
severe. Since available evidence suggests that functional MR of lesser severity may have simi-
lar or greater impact on mortality than primary MR [2], distinguishing between moderate 
and severe MR becomes of vital importance [15]. While severe primary MR is defined as 
EROA ≥ 40 mm2 and regurgitant volume ≥ 60 mL, in line with current guidelines, severe sec-
ondary MR should be diagnosed whenever EROA ≥ 20 mm2 and regurgitant volume ≥ 30 mL 
[13, 15] (Table 1) [16]. However, adequate evaluation of functional MR severity in a clinical 
setting is far more challenging. In functional MR, both regurgitant orifice and jet area depend 
strongly on the mechanism of mitral regurgitation. Functional MR severity may be overes-
timated if determined based on the jet size on color Doppler imaging, or underestimated if 
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assessed using other traditional measures of mitral regurgitation such as proximal isoveloc-
ity surface area (PISA) and vena contracta width [14]. Also the limitations of the volumetric 
method in the assessment of regurgitant volume and fraction are well-known issues [14]. 
Furthermore, low inter- and intra-observer agreement between cardiologists reviewing the 
same dataset was documented [17]. It is now known that due to the limitations inherent to 
each available method, no single parameter is accurate enough to quantify the degree of 
MR. Therefore, current guidelines recommend an integrative approach including multiple 
qualitative and quantitative parameters, along with certain signs and measures of MR sever-
ity, such as left ventricular size and function, left atrial size, mitral valve leaflet morphol-
ogy and motion, mitral filling pattern, pulmonary venous flow pattern and others [13, 16]. 
If during the first attempt MR is not unequivocally defined as mild or severe, the integrative 
approach should be used to exclude the severe character of mitral regurgitation.
Functional MR is an evidently dynamic phenomenon. A typical phasic variation in regur-
gitant volume and orifice, with the maximum values observed in early and late systole and 
minimum ones in mid-systole (at peak transmitral pressure gradient generated by LV), is 
documented [18]. This intra-beat variability (referred to as the “loitering pattern”) hinders 
functional MR assessment, which is traditionally carried out in mid-systole. The severity of 
functional MR may also show a beat-to-beat variability depending on changes in loading 
conditions and hemodynamic parameters (e.g., during arrhythmia). The dynamic nature of 
functional MR has particular practical meanings in two situations: during physical exertion 
and intraoperative assessment. Induction of anesthesia and inotropic agents may significantly 
reduce MR and thus, may directly affect intraoperative decisions regarding its repair. Owing 
the dynamic nature of functional MR, in patients whose symptoms at rest are inadequate to 
assess the severity of mitral regurgitation, more accurate information may be obtained during 
exercise echocardiography. Exercises contribute to a greater cardiac load and thus, may also 
trigger dynamic geometric changes in the LV and mitral valve apparatus (even despite the 
lack of provoked ischemia), which may eventually result in acute “flash pulmonary edema” 
[19]. This may be a reason behind worse prognosis associated with even a mild functional 
MR. An exercise-induced increase in EROA by at least 13 mm2 was shown to correlate with 
higher morbidity and mortality [20]. Exercise echocardiography may also unmask increasing 
pulmonary artery pressure and the lack of LV contractile reserve, both being important predic-
tors of the outcome [19, 20]. Finally, exercises may reveal or trigger greater LV dyssynchrony 
with increased functional MR [21]. Despite some caveats of this approach, current guidelines 
recommend echocardiographic quantification of secondary MR during exercises, as this may 
Primary (organic) MR Secondary (functional) MR
EROA ≥0.4 cm2 ≥0.2 cm2
Regurgitant volume ≥60 mL ≥30 mL
Regurgitant fraction ≥50% ≥50%
Vena contracta ≥0.7 cm —
Jet area Central jet >40% LA or holosystolic eccentric jet —
Table 1. Quantitative echocardiographic criteria for severe MR in primary and secondary disease of the mitral valve [16].
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provide prognostically important information about dynamic characteristics of this condition 
[13]. Owing to documented limitations of echocardiography in this setting, newer imaging 
techniques, such as cardiac magnetic resonance and multidetector-row computed tomogra-
phy, play an increasing role in the evaluation of patients with heart failure and functional 
MR. Both these techniques provide complementary data, such as true volumetric measures of 
cardiac chamber size and function, and can be used to assess myocardial viability and scars.
4. Pathophysiology of functional mitral regurgitation
The term “functional mitral regurgitation” refers to a dysfunction of the valve without its pri-
mary organic damage. Optimal function of the mitral valve provides nonrestrictive blood flow 
during diastole and leak tightness during systole. This diastolic and systolic competence is pos-
sible due to a synchronous coordination of all components of the mitral valve apparatus, acting 
under a balanced influence of closing and opening forces. Mitral valve apparatus is an integrated 
unit consisting of mitral valve itself (formed by two leaflets and mitral annulus) and subvalvular 
components (chordae tendineae, two papillary muscles, left ventricle and posterior left atrial 
wall). An effective function of the mitral valve is determined not only by the compatible coop-
eration between its components but also by their appropriate structural and spatial relations.
4.1. Left ventricular remodeling and dysfunction as a mechanism of functional 
mitral regurgitation
All changes in LV function and geometry affect functioning of mitral valve through opposing 
strength vectors: the tethering force (created by displacement of papillary muscles) and the 
LV-generated leaflet closing force (created by effective contraction causing transmitral pres-
sure gradient) (Figure 1) [22]. Global LV dilation results in incomplete mitral leaflet closure 
and mitral regurgitation, which correlates with LV dysfunction. Local or global dilation of 
the LV is a prerequisite for incomplete mitral leaflet closure [22]. However, functional MR 
does not result from LV dilatation per se but from an increase in LV sphericity and resultant 
posterolateral displacement of the papillary muscles [23, 24]. If functional MR has an isch-
emic etiology, it does not necessarily need to be preceded by global systolic dysfunction [25]. 
Regional abnormalities in cardiac wall motion after inferior myocardial infarction may con-
tribute to mitral valve tethering (with systolic tenting of the leaflets), which is strong enough 
to cause severe mitral regurgitation despite preserved LV ejection fraction (LVEF) [25].
Two main patterns of leaflet tethering can be distinguished in functional mitral regurgitation 
(Figure 2) [26, 27]. The symmetric pattern is characterized by global LV dilation with increased 
sphericity and predominant apical displacement of both leaflets with central regurgitant jet 
direction. Also the mitral valve annulus dilates symmetrically, primarily in the septal-lateral 
direction [26, 27]. This configuration is typical for non-ischemic functional MR (Carpentier type 
III B symmetric) [27, 28]. The asymmetric pattern is typically resulted from local remodeling of 
the posterior papillary muscle-bearing wall segment, with posterior tenting of both leaflets and 
a posteriorly directed asymmetric regurgitant jet (Carpentier type III B asymmetric) [25–28]. 
While the displacement of posterior papillary muscle is similar regardless of the leaflet tethering 
pattern, symmetric tethering is characterized by greater posterior and lateral displacement of 
Cardiac Dyssynchrony as a Pathophysiologic Factor of Functional Mitral Regurgitation: Role…
http://dx.doi.org/10.5772/intechopen.76605
61
anterior papillary muscle and longer inter-papillary distance [27]. Both patterns of leaflet tether-
ing can be observed in ischemic MR [25–27]. The occurrence of the symmetric pattern in ischemic 
MR is associated with more advanced systolic dysfunction, global remodeling and increased LV 
sphericity [23, 24, 27]. This pattern is typical for non-ischemic dilated cardiomyopathy [26].
Figure 1. Mechanism of functional mitral regurgitation. (A) Balance of closing and tethering forces acting on mitral 
leaflets during systole. (B) Disrupted balance of closing and tethering forces due to local LV remodeling (dark shading). 
LA: left atrium; LV: left ventricle; PM: papillary muscle; Ao: aorta; ME: mitral regurgitation.
Figure 2. Patterns of leaflet tenting in functional mitral regurgitation. (A) Normal coaptation of mitral leaflets. (B) 
Asymmetric pattern—predominant posterior displacement of both leaflets with prevent restriction of posterior leaflet 
and large eccentric regurgitant jet. (C) Symmetric pattern—predominant apical displacement of both leaflets with central 
regurgitant jet.
Structural Insufficiency Anomalies in Cardiac Valves62
While geometric changes of LV are an essential component of functional MR pathomecha-
nism, it is the tethering distance between the tip of posterior papillary muscle and the ante-
rior pole of mitral annulus (“posterior papillary-fibrosa distance”), which constitutes the final 
common pathway determining the plane of leaflet coaptation [22, 29]. Mitral annular dilation 
typically occurs at late stage of ischemic MR [30, 31]. Isolated dilation and flattening of mitral 
valve annulus are occasionally the cause of severe mitral regurgitation, representing type I in 
Carpentier’s classification [28, 30, 31]. Although atrial fibrillation constitutes a quite frequent 
cause of functional MR, it rarely results in severe valve dysfunction. Isolated enlargement of 
the left atrium, with concomitant atrial fibrillation or without, leads to dilatation of mitral 
annulus and reduced leaflet coaptation [32]. Diastolic MR results from a reversal of atrioven-
tricular pressure gradient during diastole. This form of MR occurs in patients with atrioven-
tricular block, cardiomyopathy and aortic regurgitation, as well as in individuals with long 
filling periods in atrial tachyarrhythmia [31].
4.2. Cardiac dyssynchrony as a pathophysiologic factor of functional mitral 
regurgitation
Dyssynchrony, defined as an uncoordinated regional myocardial contraction [33, 34], may 
manifest as (1) “primary electrical dyssynchrony” (i.e., electrical conduction delay which 
causes non-uniform timing of myocyte depolarization), (2) abnormalities in excitation-con-
traction coupling (a surrogate for regional electromechanical coupling is the interval between 
the onset of QRS complex in ECG and the onset of systolic velocity in spectral pulsed-wave 
tissue Doppler imaging), or (3) “primary mechanical dyssynchrony” (i.e., a regional delay 
in onset shortening and in time to peak shortening of LV segments) [34]. Primary electrical 
dyssynchrony is typical for left bundle branch block (LBBB) and primary mechanical dys-
synchrony—for regional ischemia or fibrosis [33, 34]. Currently, QRS duration remains the 
only clinically significant surrogate for the timing of myocardial contraction and the only 
criterion amenable for CRT [35, 36]. Clinical significance of “clear” primary mechanical dys-
synchrony remains ambiguous [37, 38]. CRT does not provide any benefit (and may be even 
harmful) in heart failure patients with mechanical dyssynchrony without QRS widening 
(<130 ms) [38]. Various echocardiographic measures of dyssynchrony turned out not to be a 
superior selection criterion for CRT [39, 40]. Moreover, unacceptable variability, poor repro-
ducibility and limited practical predictive value of the most echocardiographic parameters 
of dyssynchrony are documented [41]. Thus, although the predictive value of prolonged 
QRS also varies from study to study [42, 43], qualification to CRT is still based primarily on 
this parameter [35, 36].
Functional MR correlates strongly with QRS duration. Left bundle branch block and right 
ventricular pacing (which produce a conduction abnormality similar to LBBB), but not 
right bundle branch block or left anterior hemi-block, are strongly associated with func-
tional MR [44]. The relationship between right ventricular pacing and mitral regurgita-
tion indicates that the key determinant of functional MR is a conduction abnormality, 
rather than the underlying disease causing LBBB [44]. Those findings have important 
implications for biventricular pacing as a treatment option in heart failure patients with 
functional MR.
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LV dyssynchrony is a less important determinant of functional MR than systolic valvular tent-
ing, which is the strongest predictor of EROA [45]. However, the impact of systolic valvular 
tenting on functional MR in different subsets of patients with LV dysfunction varies. Mitral 
valve tenting and local LV remodeling (in the papillary muscle-bearing wall segments), but 
not regional dyssynchrony, are independent predictors of functional MR degree in ischemic 
LV dysfunction; these local changes result directly from ischemic lesions. In non-ischemic LV 
dysfunction, regional dyssynchrony exacerbates functional MR independently of LV geom-
etry but as a factor of lesser importance [45].
5. Effect of cardiac resynchronization therapy on functional mitral 
regurgitation
Cardiac resynchronization therapy is an established treatment option for patients with 
advanced chronic heart failure and prolonged QRS duration [35, 36]. The benefits of CRT are 
attributed mainly to increased efficiency of LV filling and ejection, resulting from the improve-
ment in atrioventricular coupling, intra- and interventricular synchronization [46–48]. CRT 
can attenuate heart failure symptoms and improve exercise capacity and survival in patients 
with heart failure and prolonged QRS duration [49–51]. In line with current ESC guidelines, 
cardiac resynchronization therapy is recommended (class I recommendation) in symptomatic 
(despite optimal medical therapy) patients with heart failure in sinus rhythm, with LBBB and 
QRS duration of at least 130 ms, with LVEF ≤ 35%, and in individuals with LV dysfunction 
(regardless of the NYHA class) who have an indication for ventricular pacing and high degree 
atrioventricular block [36]. The outcome of cardiac resynchronization therapy is determined 
by a number of clinical factors, and improvement of functional mitral regurgitation is cur-
rently considered as one of the mechanisms underlying the beneficial effect of the treatment.
Echocardiographic studies demonstrate that cardiac resynchronization therapy may correct 
the pathophysiologic determinants of functional MR. The following mechanisms are consid-
ered to mediate the clinical efficacy of CRT.
1. Restoration of the LV and papillary muscle synchronous contraction improves spatial rela-
tions and function of the subvalvular apparatus and the mitral valve itself (a decrease in 
mitral valve tethering force); the effect is specific for this therapeutic method [52, 53].
2. Improved coordination of LV wall contraction and resultant improvement of LV ejection 
function contribute to an increase in transmitral pressure gradient (greater mitral valve 
closing force); the effect is specific for this therapeutic method [54, 55].
3. Remote reverse remodeling of the LV with the reduction of LV volume and sphericity in-
duce favorable changes in the geometry of mitral valve apparatus (a decrease in tethering 
force) and contribute to further improvement in LV systolic function (an increase in mitral 
valve closing force); the effect is not specific for this therapeutic method and particularly 
pronounced at the later phase of CRT [53, 55–57].
4. The effect of cardiac resynchronization therapy on mitral valve annular size and function 
(through the recoordination of contraction in LV basal segments and then through reverse 
remodeling of the LV) is uncertain [52, 53].
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5. Optimization of atrioventricular delay with the restoration of proper timing for atrioven-
tricular synchrony/atrioventricular relaxation contributes to generation of an adequate 
transmitral pressure gradient during the cardiac cycle and eliminates diastolic MR (if pre-
sent); this effect is only partially specific for this therapeutic method [58].
5.1. Biphasic response of functional mitral regurgitation to cardiac 
resynchronization therapy
The improvement of functional MR after the use of cardiac resynchronization therapy has 
two phases:
1. Immediate, short-term functional MR reduction occurring directly after the implantation of 
a CRT device. The effect manifests as better-coordinated contraction of the papillary mus-
cle-bearing segment (diminished tethering force) and improvement of LV ejection function 
(an increase in transmitral pressure gradient—LV dP/dt, which represents the mitral valve 
closing force) [52–54]. CRT contributes primarily to a decrease in early-systolic MR [59, 60].
2. Late, long-term functional MR reduction occurring weeks to months after the implanta-
tion of a CRT device. This phase manifests primarily as reverse remodeling of the LV. A 
decrease in LV volume and sphericity induces favorable geometric changes in mitral valve 
apparatus, with the reduction of tethering force. The improvement of LV systolic func-
tion is reflected by an increase in closing force [53, 55, 57]. Attenuation of both resting 
and exercise-induced functional MR usually can be observed in this phase, along with the 
improvement of cardiopulmonary performance [61].
In fact, the two phases of functional MR improvement may be less distinct. LV reverse remod-
eling can occur relatively early [10]. Subacute improvement in systolic shape of the LV (lesser 
sphericity) and subvalvular traction after CRT implementation are also probably related to an 
increase in LV longitudinal function [56].
Effective CRT reduces the transmitral regurgitant volume in about 40% of patients immedi-
ately and in the next 20% of them at a later stage [53]. The sequence of functional MR improve-
ment may depend on a pattern of baseline dyssynchrony. Early and late responders may show 
a similar extent of LV dyssynchrony; however, the site of latest activation in early respond-
ers is mostly inferior or posterior (adjacent to the posterior papillary muscle), whereas in late 
responders, the latest activation occurs primarily in the lateral wall [53]. Late responders may 
also show acute improvement in LV end-systolic volume, presumably as an effect of recoor-
dinated and, hence, more effective LV contraction. Acting through the mechanisms described 
above, CRT can attenuate moderate-to-severe functional mitral regurgitation to a clinically non-
significant MR in about one-third of heart failure patients. Published data about the association 
between baseline functional MR and response to CRT are ambiguous [8, 62–64]. The post-CRT 
improvement of functional MR may be relatively more frequent in patients with greater sever-
ity of mitral regurgitation at the baseline. Moreover, an acute or subacute attenuation of func-
tional MR is a predictor of further improvement [8]. Lack of improvement in functional MR in 
response to CRT is associated with worse prognosis (unfavorable profile of clinical evolution, 
higher incidence of arrhythmic events and lesser occurrence of LV reverse remodeling [62, 65]). 
This raises a question about the predictors of functional MR response to CRT.
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5.2. Predictors of functional mitral regurgitation improvement in response to cardiac 
resynchronization therapy
Despite appropriate selection of candidates for CRT, not all of them respond to the treat-
ment. The mechanisms responsible for post-CRT improvement in functional MR are complex. 
Although QRS duration is the main determinant of primary electrical dyssynchrony and a 
primary criterion considered during selection of patients for CRT, it is not a good predictor 
of response to the treatment [42, 43]. Aside from dyssynchrony, the post-CRT improvement 
in functional MR may also depend on other factors, such as myocardial viability, presence of 
scar/fibrosis and the extent of LV remodeling at the baseline [10, 66, 67].
Many echocardiographic measures of dyssynchrony do not confirm their value as the predic-
tors of CRT outcomes [39–41]. Inter-ventricular mechanical delay (IVMD, the time difference 
between right ventricular and left ventricular ejection, determined as the time elapsed since 
the onset of the QRS to the onset of left ventricular vs. right ventricular ejection, usually mea-
sured using pulsed Doppler flow) seems to be a simple and reproducible parameter of dyssyn-
chrony, correlating well with the response to CRT, either LV reverse remodeling or functional 
MR improvement [10, 41, 68, 69]. Also, speckle-tracking radial strain imaging (time difference 
in peak septal to posterior wall strain) appears as a relatively simple measure of dyssynchrony, 
having established a predictive value with regard to CRT outcome [67]. There is no unam-
biguous evidence regarding the site of the latest activation as an independent predictor of the 
improvement in functional MR [10, 53]. Myocardial viability (in heart failure with ischemic 
etiology) and contractile reserve (in non-ischemic cardiomyopathy) are important determinants 
of CRT effectiveness in terms of functional MR improvement [10, 70–73]. The outcome of CRT 
may be also associated with the location of contractile reserve (particularly in relation to the 
papillary muscle-bearing segments and to the paced LV region), as well as with the size of the 
contractile reserve area [10, 66, 72, 73]. The importance of discordant LV lead position and myo-
cardial scar, especially extensive scar burden, as the predictors of CRT outcomes, is documented 
[74, 75]. The potential role of myocardial fibrosis stimulates research on biochemical predictors 
of CRT responses (among them on galactin-3, a protein involved in fibrogenesis) [76].
5.3. Functional mitral regurgitation improvement and left ventricular reverse 
remodeling in response to CRT
The change in LV end-diastolic volume after the use of cardiac resynchronization ther-
apy proved to be the most powerful independent predictor of death [77]. CRT effectively 
reversed LV remodeling, both in patients with moderate-to-severe heart failure (NYHA III/
IV class) and in individuals with mild heart failure (NYHA I/II class) [49, 50]. The response 
to CRT may be influenced by the presence of functional mitral regurgitation prior to the 
implantation of a CRT device and by its persistence despite the treatment. Patients, who do 
not respond to CRT, present with a significant functional MR more often than the respond-
ers [78]. On the other hand, an improvement in pre-existing functional MR contributes to 
LV reverse remodeling during follow-up after the implantation of a CRT device [60]. The 
incidence of reverse remodeling, defined as an improvement in LVEF and forward stroke 
volume, is the highest in patients who show a reduction of total functional MR, intermediate 
in individuals with mild functional MR or lack thereof at the baseline and the lowest in 
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persons who do not show an improvement in total functional MR after 3 months of post-
CRT follow-up [60]. Correlation between clinical and echocardiographic indices of post-CTR 
improvement is rather weak [10, 77]. However, the direction and magnitude of LV reverse 
remodeling correlate with survival, and a 1-year mortality after CRT implementation is pre-
dicted by echocardiographic parameters, rather than by clinical indices [77].
Finally, volumetric limitation for functional MR improvement in response to cardiac resynchro-
nization therapy needs to be emphasized. Not only irreversibly damaged ischemic myocytes 
respond less to CRT, the post-CRT improvement in functional MR is also less likely in patients 
who present with greater degree of LV dilatation at the baseline. Lesser baseline LV diameters 
(end-diastolic and end-systolic) and volumes are the independent predictors of functional 
MR improvement in response to CRT [10, 67, 79–81]. The cut-off value for LV end-diastolic 
dimension is close to 75 mm [10, 82] and for LV end-systolic dimension index 29 mm/m2 
 [67]. Non-responders present a significantly higher baseline LV dilatation. CRT may be insuf-
ficient to overcome poor natural history of systolic heart failure but may slow down its pro-
gression. The effectiveness of all currently available therapeutic options is limited, and critical 
enlargement of the left ventricle may trigger the previously mentioned vicious circle of self-
perpetuating LV dilatation and functional mitral regurgitation [10, 83, 84].
6. Management of patients with persistent significant functional 
mitral regurgitation after the use of CRT
Therapeutic targets in patients with functional MR include attenuation of symptoms, lesser 
number of heart failure hospitalizations, better quality of life and, potentially, survival. At 
present, the most effective therapies of functional MR are aimed at the underlying LV dysfunc-
tion. Therefore, as the first step, optimal medical therapy according to the guidelines for the 
management of heart failure should be used [36]. As the second step, whenever appropriate, 
CRT should be implemented in line with the respective guidelines [35, 36]. In patients who 
remain symptomatic despite optimal medical therapy and CRT (if indicated), mitral valve 
intervention (surgical or transcatheter repair) should be considered; however, there is no evi-
dence that a reduction of functional MR improves survival [13]. Moreover, the surgery has 
never clearly been demonstrated to alter the natural history of the primary disease (dilated 
cardiomyopathy) [85]. Limited empirical data contribute to a lower level of evidence for man-
agement recommendations, highlighting the importance of decisions made by the Heart Team. 
The multidisciplinary Heart Team consisting of imaging experts, heart failure and electro-
physiology specialists, interventional cardiologists, and cardiac surgeons should try to reach 
a consensus on appropriate care. Not only the feasibility of the procedure but also comorbidi-
ties, the level of surgical risk, and surgeon experience should be considered [13]. In patients 
undergoing revascularization, the evaluation and decision to treat (or not to treat) ischemic 
MR should be made prior to surgery. There is an overall agreement that severe functional 
MR should be addressed at the time of coronary artery bypass grafting (CABG). The man-
agement of moderate functional MR in patients undergoing CABG still raises controversies 
[86]. The thresholds of functional MR severity are also a matter of debate (as stated earlier). 
Surgical options in patients with functional MR include mitral valve repair and replacement. 
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Mechanical LV-assisted devices and heart transplantation should be considered in the most 
advanced stage of heart failure.
The controversies regarding an optimal surgical approach should be emphasized [87]. After 
surgical annuloplasty (undersized complete ring to restore leaflet coaptation), residual or 
recurrent functional MR is frequently observed (in approximately one-third of the cases) 
[88]. Valve-sparing mitral valve replacement techniques (leaving the leaflet and subvalvular 
apparatus intact to preserve the LV function) should be considered in patients with echo-
cardiographic predictors of repair failure (Table 2) [88]. The surgery should also be consid-
ered in heart failure patients with severe functional MR and LVEF <30% but with an option 
for CABG and the evidence of myocardial viability. Qualification for surgical treatment of 
functional MR should be restrained if concomitant revascularization is not indicated [89].
Percutaneous edge-to-edge repair (MitraClip device) for FMR is a low-risk procedure and may 
be considered in patients during high surgical risk, whenever feasible [90]. The treatment may 
attenuate symptoms, improve quality of life and promote LV reverse remodeling but is infe-
rior to surgical methods in terms of functional MR reduction. Valve intervention is generally 
contraindicated in patients with LVEF < 15% [13]. Two investigational extracardiac devices, 
CorCap (Acorn Cardiovascular) [91] and Coapsys (Myocor, Inc., Maple Grove, Minnesota) 
[92], which have been used to reshape the LV and thus to reduce the degree of functional MR, 
remained an interesting experiment. In cases of more advanced LV dysfunction (LVEF ≤ 30%) 
with no option for CABG, the Heart Team should choose between a palliative treatment of 
functional MR (surgical or transcatheter procedures, ventricular assist devices, heart trans-
plantation) and a conservative therapy, after careful individual appraisal of the patient [13].
7. Conclusion
Irrespective of heart failure etiology, functional mitral regurgitation has a significant unfavor-
able impact on prognosis. The benefits of surgical treatment in functional mitral regurgitation 
Mitral valve deformation Coaptation distance ≥1 cm
Tenting area > 2.5–3 cm2
Complex jets originating centrally and posteromedially
Posterolateral angle >45° (high posterior leaflet tethering)
Local LV remodeling Interpapillary muscle distance >20 mm
Posterior papillary-fibrosa distance >40 mm
Lateral wall motion abnormality
Global LV remodeling EDD >65 mm, ESD >51 mm (ESV >140 mL) (low likelihood of reverse LV remodeling after 
repair and poor long-term outcome)
Systolic sphericity index >0.7
EDD, end-diastolic diameter; ESD, end-systolic diameter; ESV, end-systolic volume; LV, left ventricle.
Table 2. Unfavorable TTE characteristics for mitral valve repair in secondary MR [88].
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are unclear and thus, resynchronization therapy remains a valuable option in eligible patients. 
Indications for such treatment should be considered as early as possible, before the develop-
ment of a severe left ventricular dilatation, a predictor of failure in resynchronization therapy.
Acronyms and abbreviations
CABG coronary artery bypass grafting
CRT cardiac resynchronization therapy
EROA effective regurgitant orifice area
HF heart failure
LBBB left bundle branch block
LV left ventricle
LVEF left ventricular ejection fraction
MR mitral regurgitation
NYHA New York Heart Association
PISA proximal isovelocity surface area
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